Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Daybue Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Daybue Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and quantity-limit approval for Daybue oral solution and Daybue stix oral powder packets for Boeing commercial members. Coverage is evaluated for patients with classic or typical Rett syndrome under the specified clinical and quantity-limit criteria.

    Policy Summary
    PayerPrime Therapeutics
    PolicyDaybue Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 15, 2026
    Next Review DateN/A
    Key ActionSubmit chart notes documenting the disease-causing mutation in the MECP2 gene.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsApproval length
    9 kg+Minimum patient weight
    200 mg/mLOral solution strength
    5,000/6,000/8,000 mgStix strengths

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    8 bottles/30 days
    Oral solution limit
    60–120 packets/30 daysStix limits

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • ALL of the following

      • The patient has a diagnosis of classic/typical Rett syndrome (RTT).
      • The patient has a disease-causing mutation in the MECP2 gene.

        Chart notes required.

      • ONE of the following

        • The patient's age is within FDA labeling for the requested indication for the requested agent.
        • There is support for using the requested agent for the patient's age for the requested indication.
      • The patient's weight is 9 kg or greater.>= 9 kg
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., geneticist, neurologist, pediatrician), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • The patient does NOT have any FDA-labeled contraindications to the requested agent.

    Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's Prior Authorization process.

      Patients not previously approved for the requested agent will require initial evaluation review.

    • The patient has had clinical benefit with the requested agent.
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., geneticist, neurologist, pediatrician), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • The patient does NOT have any FDA-labeled contraindications to the requested agent.

    Quantity-Limit Approval

    The requested quantity (dose) is covered when ONE of the following is met:

    ONE of the following

    • The requested quantity (dose) does NOT exceed the program quantity limit.
    • ALL of the following

      • The requested quantity (dose) exceeds the program quantity limit.
      • ONE of the following

        • BOTH of the following

          • The requested agent does NOT have a maximum FDA-labeled dose for the requested indication.
          • There is support for therapy with a higher dose for the requested indication.

    Key Clinical Threshold

    Minimum Patient Weight
    Minimum patient weight9 kg or greater
    Applies toInitial approval
    Approval period12 months

    Prior Authorization and Documentation

    Prior Authorization

    Initial Prior Authorization

    Submit an initial prior authorization request documenting that the patient meets all clinical approval requirements for Daybue. Initial approval is limited to 12 months.

    • Diagnosis of classic/typical Rett syndrome (RTT).
    • Disease-causing MECP2 gene mutation, with chart notes required.
    • If an FDA-labeled indication applies, the patient's age is within FDA labeling or there is support for use at the patient's age for the requested indication.
    • Patient weighs 9 kg or greater.
    • Prescriber is a specialist in the area of the patient's diagnosis (for example, geneticist, neurologist, or pediatrician), or has consulted with such a specialist.
    • Patient has no FDA-labeled contraindication to Daybue.
    Prior Authorization

    Renewal Prior Authorization

    For renewal, document continued eligibility and clinical benefit. Renewal approval is limited to 12 months.

    Therapy Overview

    Daybue (trofinetide) is a therapy for patients with Rett syndrome. This policy applies to patients with classic or typical Rett syndrome associated with a disease-causing mutation in the MECP2 gene. Initial approval also requires a patient weight of 9 kg or greater and appropriate specialist prescribing or consultation.

    Daybue Initial Approval

    Daybue Initial Approval Criteria

    Initial Evaluation: Daybue (trofinetide) will be approved when ALL of the following are met.

    Daybue initial therapy

    • Patient eligibility

      • Diagnosis and genetic confirmation: The patient has a diagnosis of classic/typical Rett syndrome (RTT) AND a disease-causing mutation in the MECP2 gene.

        Chart notes are required for the disease-causing MECP2 mutation.

      • Age requirement when FDA-labeled indication applies

        • The patient's age is within FDA labeling for the requested indication for the requested agent.
        • There is support for using the requested agent for the patient's age for the requested indication.

    Daybue Renewal

    Daybue Renewal Criteria

    Renewal Evaluation: Daybue (trofinetide) will be approved when ALL of the following are met.

    Daybue renewal

    • Previous approval: The patient has been previously approved for the requested agent through the plan's Prior Authorization process.

      Patients not previously approved for the requested agent require initial evaluation review.

    • Clinical benefit: The patient has had clinical benefit with the requested agent.
    • Prescriber expertise

      • The prescriber is a specialist in the area of the patient's diagnosis, such as a geneticist, neurologist, or pediatrician.

    Daybue Quantity Limits

    Quantity Limit
    MedicationDaybue (trofinetide oral solution), 200 mg/mL
    Quantity limit8 bottles per 30 days
    Dose formBottles
    Quantity Limit
    MedicationDaybue stix (trofinetide oral powder packet), 5,000 mg
    Quantity limit120 packets per 30 days
    Dose formPackets
    Policy Summary
    PayerPrime Therapeutics
    PolicyDaybue Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 15, 2026
    Next Review DateN/A
    Key ActionSubmit chart notes documenting the disease-causing mutation in the MECP2 gene.
    SourceLink
    On This Page
    Coverage CriteriaKey Clinical ThresholdPrior Authorization and DocumentationTherapy OverviewDaybue Initial ApprovalDaybue RenewalDaybue Quantity Limits
  1. BOTH of the following

    • The requested quantity (dose) does NOT exceed the maximum FDA-labeled dose for the requested indication.
    • There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit.
  2. BOTH of the following

    • The requested quantity (dose) exceeds the maximum FDA-labeled dose for the requested indication.
    • There is support for therapy with a higher dose for the requested indication.
    • Patient was previously approved for Daybue through the plan's prior authorization process; patients without prior approval require initial evaluation.
    • Patient has had clinical benefit with Daybue.
    • Prescriber is a specialist in the area of the patient's diagnosis, or has consulted with such a specialist.
    • Patient has no FDA-labeled contraindication to Daybue.
    Documentation Required

    MECP2 Mutation Documentation Required

    Include chart-note documentation confirming a disease-causing mutation in the MECP2 gene as part of the initial request for Daybue.

    • The diagnosis must be classic/typical Rett syndrome (RTT).
    Documentation Required

    Document Clinical Benefit for Renewal

    Renewal requests must document that the patient has experienced clinical benefit with Daybue. Continued approval also requires prior plan approval, specialist involvement or consultation, and no FDA-labeled contraindication.

    • Describe the patient's clinical response or benefit from ongoing Daybue therapy.
    • A patient not previously approved through the plan's prior authorization process requires initial evaluation.
    Documentation Required

    Support a Quantity-Limit Exception

    If the requested Daybue quantity exceeds the program quantity limit, submit documentation supporting one of the permitted quantity-limit exceptions. Quantity-limit exception approval is limited to 12 months.

    • If Daybue has no maximum FDA-labeled dose for the requested indication: provide support for therapy with a higher dose.
    • If the requested quantity does not exceed the maximum FDA-labeled dose: provide support explaining why the quantity cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.
    • If the requested quantity exceeds the maximum FDA-labeled dose: provide support for therapy with a higher dose.

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Denial Risk

    Quantity-Limit Exception Not Supported

    A quantity-limit exception will not be approved when the requested quantity exceeds the program limit and the request lacks support for an applicable exception.

    • The request does not document that the quantity is within the maximum FDA-labeled dose when that condition is required.
    • No support is provided for therapy with a higher dose when the requested quantity exceeds the maximum FDA-labeled dose or when no maximum FDA-labeled dose applies.
    • When a lower quantity of a higher strength could be used, no support is provided explaining why that alternative cannot achieve the requested quantity without exceeding the program quantity limit.
  3. Weight requirement: The patient's weight is 9 kg or greater.>= 9 kg
  4. Prescriber expertise

    • The prescriber is a specialist in the area of the patient's diagnosis, such as a geneticist, neurologist, or pediatrician.
    • The prescriber has consulted with a specialist in the area of the patient's diagnosis.
  5. Safety: The patient does NOT have any FDA-labeled contraindications to the requested agent.
  6. The prescriber has consulted with a specialist in the area of the patient's diagnosis.
  7. Safety: The patient does NOT have any FDA-labeled contraindications to the requested agent.
  8. Quantity Limit
    MedicationDaybue stix (trofinetide oral powder packet), 6,000 mg
    Quantity limit120 packets per 30 days
    Dose formPackets
    Quantity Limit
    MedicationDaybue stix (trofinetide oral powder packet), 8,000 mg
    Quantity limit60 packets per 30 days
    Dose formPackets